TELEFLEX INC 8-K

What Happened

• Teleflex Incorporated announced on April 30, 2026 that Jason Weidman (age 51) will become the Company’s President and Chief Executive Officer effective June 8, 2026. The Board expects to appoint him as a director as of that Start Date. Interim CEO Stuart A. Randle will be replaced as CEO but will remain a member of the Board. The appointment and related transition were also disclosed in a company press release (Exhibit 99.1).

Key Details

• Offer letter dated April 26, 2026: annual base salary of $1.0 million and target annual cash bonus equal to 125% of base salary (2026 paid at no less than prorated target).
• Equity and sign‑on awards: annual equity award target of $7.0 million beginning 2027; sign‑on restricted stock grant with grant‑date fair value of $7.0 million (vesting in ~4 equal annual installments); stock options with grant‑date fair value of $1.0 million (vesting in ~3 equal annual installments).
• Additional sign‑on and relocation: up to $800,000 cash payment (payable Dec 31, 2026) to replace forfeited prior employer incentives; relocation benefits (temporary housing, rental car up to 12 months, travel, primary home relocation reimbursements, tax equalization and up to $15,000 other expenses); certain legal fee reimbursement. Relocation benefits must be repaid if employment ends within three years except for resignation for good reason or termination without cause.
• Severance and change‑of‑control protections: standard Senior Executive Severance Agreement (24 months of continued base salary, vehicle allowance, health coverage at active rates, up to $20,000 outplacement, prorated/previous-year bonus treatment) and Executive Change of Control Agreement (36‑month severance period, possible lump sum bonus payments, 300% of target bonus on termination in connection with a change of control, continued deferred compensation contributions if applicable, and acceleration of unvested equity). Post‑termination covenants include 24‑month non‑solicit (employees) and, after relocation to Wayne, PA, 24‑month non‑compete and non‑solicit (customers), perpetual confidentiality, and mutual non‑disparagement.

Why It Matters

• This 8‑K documents a planned CEO transition to an external, senior medtech executive with two decades at Medtronic and significant vascular business experience; the change is effective June 8, 2026 and the Board will add him as a director. For investors, the filing also details substantial compensation and sign‑on packages (cash, large restricted stock and option grants) and severance/change‑of‑control protections that could affect future cash outlays and equity dilution if awards vest or accelerate under certain termination scenarios.